Clinical Trials Logo

Norwalk Gastroenteritis clinical trials

View clinical trials related to Norwalk Gastroenteritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05916326 Not yet recruiting - Clinical trials for Norovirus Infections

Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha)

Start date: June 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the Efficacy, Safety and Immunogenicity of the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha) in Healthy People Aged 6 Months to 13 Years After Vaccination

NCT ID: NCT04941261 Recruiting - Clinical trials for Norovirus Infections

Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)

Start date: June 30, 2021
Phase: Phase 2
Study type: Interventional

Phase II clinical study will explore dose and safety, immunogenicity in 4 age groups, including 18-59 years old group, 6-17 years old group, 3-5 years old group, 6-35 months old group, with a total of 1716 subjects.

NCT ID: NCT04188691 Completed - Clinical trials for Norovirus Infections

A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine

Start date: November 28, 2019
Phase: Phase 1
Study type: Interventional

A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.